Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It provides a proof-of-principle that co-targeting AR and PRDX1 may be more effective to control PCa growth.
|
31477836 |
2020 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The function of NE cells in PCa remains poorly understood, and one important characteristic of these cells is their lack of expression of AR and resistance to hormonal therapy.
|
30924452 |
2020 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of AR in metastatic PC was up regulated, indicating the importance of AR signaling in the progression of this cancer.
|
31783154 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor (AR) plays a pivotal role in the development of male sex and contributes to prostate cancer growth.
|
31057123 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recent availability of selective AR inhibitors (e.g. bicalutamide, enzalutamide, apalutamide) approved for the treatment of prostate cancer has opened up the possibility to use them in BC patients whose tumors express AR.
|
31002873 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
5α-Dihydrotestosterone (5α-DHT) possesses a great affinity for the androgen receptor (AR), and its binding to AR promotes the proliferation of prostate cancer (PC) cells in androgen-dependent PC.
|
31753699 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inflammation is implicated in PCa initiation and progression and we have previously reported that the inflammatory cytokine, interleukin-1 (IL-1), represses AR messenger RNA (mRNA) levels and activity in AR-positive (AR<sup>+</sup> ) PCa cell lines concomitant with the upregulation of prosurvival biomolecules.
|
31730277 |
2020 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, we also showed that circZMIZ1 could increase the expression of androgen receptor (AR) and androgen receptor splice variant 7 (AR-V7), which may be partly contributed to the occurrence and development of prostate cancer.
|
31686520 |
2020 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The growth of PCa cells is stirred up by androgens and androgen receptor (AR).
|
31818479 |
2020 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
|
31799745 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, IL8 expression in the tumor microenvironment is associated with aggressive prostate cancer and with AR loss in metastatic disease.
|
31604846 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate cancer development and progression is largely dependent on androgen receptor (AR) signaling.
|
31804970 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanistically, KIF4A and AR form an auto-regulatory positive feedback loop in prostate cancer: KIF4A binds AR and AR-V7 and prevents CHIP-mediated AR and AR-V7 degradation; AR binds the promoter region of KIF4A and activates its transcription.
|
31796514 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advanced prostate cancer is often treated with anti-androgens which target the androgen receptor (AR) on which the growth of the tumour depends.
|
31778359 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results provide the first detailed mechanism of how the AR can differentially alter PCa and BCa metastasis; thus, targeting the newly identified AR-miR-525-5p-SLPI axis may help suppress metastasis.
|
31843555 |
2020 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we found that adding R-2HG or the mutant IDH1 R132H could promote PCa cell invasion in androgen receptor (AR)-negative PC3 cells or suppressing the AR in AR-positive C4-2 cells.
|
31846689 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings illustrate a previously unknown regulatory mechanism in prostate cancer cell proliferation regulated by the MSI2-AR axis and provide novel evidence towards a strategy against prostate cancer.
|
31833612 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we will summarize our current knowledge on the roles of JNK in the apoptosis, proliferation, migration and DNA repair as well as dissect the relationships between JNK and androgen receptor in prostate cancer.
|
31810118 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although AR plays a key role, it is likely that other molecular pathways also contribute to PC, making it essential to identify and develop drugs against novel targets.
|
31769890 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The heat shock protein 70 inhibitor VER155008 suppresses the expression of HSP27, HOP and HSP90β and the androgen receptor, induces apoptosis, and attenuates prostate cancer cell growth.
|
31222811 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies targeting the androgen receptor (AR) signaling pathway in aromatase inhibitor (AI)-resistant breast cancer are limited.Bicalutamide, one of the commonly used AR inhibitors in prostate cancer, in combination with AI, did not show synergistic activity in patients with estrogen receptor-positive and AI-resistant disease in this phase II, single-arm study.The clinical benefit rate and objective response rate at 6 months were 16.7% and 0%, respectively, and the study was terminated after the first stage.
|
31434793 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we will provide a comprehensive view of the effects of taxanes on androgen receptor signaling in prostate cancer.
|
29900882 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen and AR can stimulate both primary PC and castration-resistant PC.
|
31693255 |
2020 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deregulation of ARs has a vital role in the initiation and progression of PCa.
|
31599460 |
2020 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prostate cancer (PCa) progression is characterized by increased expression and transcriptional activity of the androgen receptor (AR).
|
31756402 |
2020 |